Teva Pharmaceuticals and Direct Relief launched a nationwide program in 2009 to assist people with asthma who did not have insurance. At the end of 2008, the FDA and EPA banned the use of chlorofluorocarbon (CFC) inhalers, which required the transition to environmentally friendly hydrofluoroalkane (HFA) inhalers. This ban resulted in a financial strain on safety net providers, given that the price of a HFA inhaler is more than triple that of a CFC inhaler. Without a generic HFA inhaler on the market, uninsured people with asthma – some 2.5 million Americans – had an even harder time accessing HFA inhalers. For those with asthma, this could result in a number of serious, sometimes life-threatening complications.  To address this, Teva donated 500,000 ProAir® HFA inhalers to Direct Relief for distribution among our clinic partners throughout the U.S.


Contact Information

Direct Relief
Email & Contact Form
27 S. La Patera Lane
Santa Barbara, CA 93117
Phone: (805) 964-4767

Federal Tax ID : 95-1831116

Privacy Policy | Donation Policy

Awards & Recognition

awards ratings

Licenses & Accreditation

vawd accreditation

©2016 Direct Relief. All rights reserved.